Reparixin is under clinical development by Dompe Farmaceutici and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Infants were admitted to the NICU with difficulty breathing, low oxygen levels, or bluish discoloration of the skin, either occurring right ... determine independent risk factors for acute respiratory ...

Patients were excluded if they had any of the following: biochemical or electrical evidence of an acute myocardial infarction ... high frequency oscillation or other advanced respiratory support ...

BIO-11006 is under clinical development by BioMarck Pharmaceuticals and currently in Phase II for Osteosarcoma.

This may lead to acute respiratory distress syndrome and severe illness. Vitamin D interacts with the ACE2 receptors, potentially preventing the virus from binding to them and reducing ...

I would have been bored, except the pain was so tiring that I could barely function. I spent the days shuffling around the ...

Feel like your skin is looking a bit tired and old ... approved for the treatment or prevention of COVID-19, acute respiratory distress syndrome (ARDS), or any other complication related to ...

Hospitals in the Netherlands are being forced to delay scheduled surgeries and other planned care for children as the seven ...

Here are a few things to note: Destroys The Skin Layer: The skin ... leading to breathing difficulties or acute respiratory distress syndrome (ARDS). The heart must work harder to pump blood ...

1 It is also important to consider that mortality due to VGS bacteremia ranges between 2 and 21%, 2 mainly as a result of septic shock and acute respiratory distress syndrome. Due to the challenge in ...